DETERMINING THE VALUE OF OCREVUS (R) (OCRELIZUMAB) FOR THE TREATMENT OF MULTIPLE SCLEROSIS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)

Alerany, C.Fernandez, R.Landete, L.Rodriguez, A.Sandoval, S.Valdivia, M.Gil, A.2025-01-072025-01-072018-10-011098-3015https://hdl.handle.net/10668/27568enDETERMINING THE VALUE OF OCREVUS (R) (OCRELIZUMAB) FOR THE TREATMENT OF MULTIPLE SCLEROSIS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)conference outputopen access10.1016/j.jval.2018.09.20641524-4733http://www.valueinhealthjournal.com/article/S109830151835366X/pdf459985603280